Introduction
============

Thalassemia is one of the most common monogenetic diseases in Southern China, Southeast Asia and the Mediterranean region ([@b1-mmr-22-02-1547]). The frequency of carriers in Guangxi, China is 26.9% for α-thalassemia (OMIM 604131) ([omim.org](omim.org)) and 19.9% for β-thalassemia (OMIM 603902) ([@b2-mmr-22-02-1547]). Thalassemia is a form of hemolytic anemia caused by an imbalance in the rate of synthesis of α- and β-globin peptide chains, due to mutation or deletion of the human α- or β-globin gene ([@b3-mmr-22-02-1547]). The two most common types of thalassemia are α-thalassemia and β-thalassemia ([@b1-mmr-22-02-1547]). Genes associated with α-thalassemia include hemoglobin α locus 2 (HBA2; OMIM 141850) and HBA1 (OMIM 141800). β-thalassemia is associated with the hemoglobin subunit β (HBB) gene (OMIM 141900) ([@b4-mmr-22-02-1547]). Moreover, \~7% of the global population is estimated to carry the genes associated with thalassemia and the birth rate of children with hemoglobin disorders is \>2.4% per year ([@b5-mmr-22-02-1547]). As thalassemia has no effective treatment ([@b6-mmr-22-02-1547]), prenatal diagnosis is an important medical requirement for thalassemia prevention strategies ([@b7-mmr-22-02-1547]). Amniocentesis and chorionic villus sampling are two commonly used invasive prenatal diagnostic procedures. However, these traumatic operations may cause injury to the fetus, miscarriage or intrauterine infection ([@b8-mmr-22-02-1547]). Furthermore, anxiety associated with these invasive procedures has been reported by numerous pregnant women ([@b9-mmr-22-02-1547]). Therefore, non-invasive prenatal diagnostic techniques for thalassemia detection are urgently required.

Since the presence of cell-free fetal DNA (cffDNA) in maternal plasma during pregnancy was first reported in 1997 ([@b10-mmr-22-02-1547]), great efforts have been made to use this source of fetal material for non-invasive prenatal diagnosis ([@b11-mmr-22-02-1547]). Non-invasive prenatal testing (NIPT) has been established for the detection of fetal chromosomal abnormalities, such as chromosome 21, 18 or 13 aneuploidy, in the plasma of pregnant women, and major variations in copy number can be rapidly detected for clinical prenatal screening and diagnosis ([@b12-mmr-22-02-1547],[@b13-mmr-22-02-1547]). In addition to NIPT for fetal aneuploidies, non-invasive testing techniques for monogenic diseases are also being developed ([@b14-mmr-22-02-1547]). A challenge facing this field is the need to target low concentrations of fetal mutations that differ by only one or a few nucleotides from the overwhelming background of maternal DNA in the mother\'s plasma ([@b15-mmr-22-02-1547],[@b16-mmr-22-02-1547]). At present, assessing the relative mutation dosage and the relative haplotype dosage (RHDO) are the main analytical approaches used for NIPT of monogenic diseases ([@b17-mmr-22-02-1547]--[@b20-mmr-22-02-1547]). Early attempts to diagnose monogenic diseases focused on approaches targeting paternally inherited fetal mutations absent from the maternal genome. This strategy has proven to be successful for the detection of achondroplasia ([@b21-mmr-22-02-1547]), myotonic dystrophy ([@b22-mmr-22-02-1547]) and Huntington\'s disease ([@b23-mmr-22-02-1547]). However, to assess fetal mutations in maternal plasma that share the same genetic identity between the mother and the fetus, more sophisticated strategies are required. These approaches have been facilitated by technological advances, including massively parallel sequencing ([@b24-mmr-22-02-1547]) and digital PCR ([@b25-mmr-22-02-1547]), which enable the sensitive and precise measurement of circulating plasma DNA. However, the large target region used for these methods substantially increase the cost of sequencing ([@b26-mmr-22-02-1547]), a factor which may impede their clinical application. Furthermore, these methods have not yet been applied for the detection of large deletion mutations.

In the present study, a technique was described for non-invasive prenatal detection of paternal and maternal mutations associated with α- and β-thalassemia using multiplex PCR or target capture combined with next-generation sequencing (NGS). Furthermore, the present study demonstrated the feasibility of using NGS data to detect targeted copy number variations (CNVs) and single nucleotide variations (SNVs) ([@b3-mmr-22-02-1547]).

Materials and methods
=====================

### Sample collection and DNA extraction

A total of eight families were recruited at The Third Affiliated Hospital of Sun Yatsen University. A total of 24 samples of peripheral blood (\~10 ml per sample) of known thalassemia genotypes were collected. There were 13 female and 11 male patients with thalassemia, with an age range of 2--38 years (mean age, 15 years). The maternal plasma of pregnant women was collected at an average gestation period of 20 weeks for non-invasive prenatal diagnostic assays. A total of \~10 ml amniotic fluid was also collected for direct molecular diagnosis. In addition, \~5 ml peripheral blood from the parents and their first child was collected into EDTA tubes. For each sample, genomic DNA (gDNA) was extracted using the DNeasy Blood and Tissue kit (Qiagen Sciences, Inc.). genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen Sciences, Inc.), according to the manufacturer\'s instructions.

Moreover, \~2 ml plasma was separated in two steps from each sample obtained from a pregnant woman. First, 5 ml peripheral blood from the pregnant women was centrifuged at 1,600 × g for 15 min at 4°C. Subsequently, \~2 ml supernatant was centrifuged at 16,000 × g for 10 min at 4°C. The plasma cffDNA was extracted using the QIAamp Circulating Nucleic Acid kit (Qiagen Sciences, Inc.), according to the manufacturer\'s instructions., then quantified using a Qubit^®^ fluorometer (Thermo Fisher Scientific, Inc.) and stored at −20°C until further use.

### Molecular genetic diagnosis of thalassemia

DNA extracted from amniotic cells of pregnant women was amplified with the α-thalassemia Genetic Deletion diagnostic kit using the gap-PCR method (Daan Gene Co., Ltd.). The thermocycling conditions were as follows: i) 96°C for 5 min, 98°C for 45 sec; ii) 10 cycles at 65°C for 1.5 min, 72°C for 3 min; iii) 25 cycles at 98°C for 30 sec, 65°C for 45 sec and 72°C for 3 min; and iv) 13 min at 72°C in a reaction volume of 25 µl with 50 ng genomic DNA (primer sequences not commercially available). The target products detected by agarose gel electrophoresis are shown in [Table SI](#SD1-mmr-22-02-1547){ref-type="supplementary-material"}.

For samples in which HBA2 levels were below the normal range (2.5--3.5%) a β-thalassemia Mutation Genetic diagnostic kit (DaAN Gene Co., Ltd.) was used. The thermocycling conditions were: i) 50°C for 15 min; ii) 95°C for 10 min; iii) 94°C for 1 min; iv) 35 cycles at 55° for 30 sec, 72°C for 30 sec; and v) 5 min at 72°C in a reaction volume of 25 µl with 50 ng genomic DNA (primer sequences not commercially available). The PCR products were hybridized with the membrane strip at 43°C for 2 h, and subsequently the membranes were washed (washing reagent supplied as part of the kit) for 15 min, incubated at 25°C for 30 min, shaken and washed twice for 10 min. The film was subsequently washed for 2 min, then according to the instructions of the present solution and displayed at 25°C for 15 min. The results were determined by observing the presence of blue spots over the whole membrane, with blue spots at the mutation site representing the presence of the mutation.

### Primer and probe design

For α-thalassemia, primers and probes were designed using the reference sequence for chromosome 16 (GenBank accession no. NC_000016.9; range, 222,846-223,709). For β-thalassemia, the reference sequence for chromosome 11 was used (GenBank accession no. NC_000011.9; range, 5,246,696-5,248,301). Reference sequences were obtained from the GenBank repository ([ncbi.nlm.nih.gov/genbank](ncbi.nlm.nih.gov/genbank)). The up- and downstream 10 kb regions of HBA and HBB, with 195 single nucleotide polymorphisms (SNPs) associated with α-thalassemia and 275 SNPs with β-thalassemia, were screened from the dbSNP database ([ncbi.nlm.nih.gov/SNP/](ncbi.nlm.nih.gov/SNP/)) using Ion AmpliSeq Designer ([ampliseq.com/](ampliseq.com/)) and the Agilent Sure Design website ([earray.chem.agilent.com/suredesign/home.htm](earray.chem.agilent.com/suredesign/home.htm)). The SNP site selection criteria used in the database were: i) SNP loci in the 1,000 Genomes Project database (gloshospitals.nhs.uk/about-us/research-our-hospitals/100000-genomes-project/) from North and South China; ii) minor allele frequency (MAF) ≥20%; iii) location of the SNP 100 bp sequence within a specific region; iv) no homology identified in the genome; v) guanine-cytosine content \>45 and \<70%; and vi) the SNP did not result in three consecutive identical bases. The Ion AmpliSeq Thalassemia panel was manufactured by Thermo Fisher Scientific, Inc., which consisted of four primer pools comprising 1,354 pairs of primers for α-thalassemia and 361 pairs of primers for β-thalassemia. The thalassemia probes were constructed by Agilent Technologies, Inc., with a target region size of \~274 kb

### Library construction

gDNA from the parents was used for library construction using the Life Technologies™ Ion AmpliSeq Library kit v. 2.0 (Thermo Fisher Scientific, Inc.), as follows: 10 ng gDNA, 4 µl 5X Ion AmpliSeq HiFi mix, 10 µl 2X Ion AmpliSeq primer pool and 4 µl nuclease-free water were mixed per reaction to amplify the target regions. Subsequently, 2 µl FuPa reagent was added to each amplified sample to partially digest the primer sequences, and each library was ligated to a unique barcode and universal adapter in the form of Life Technologies™ Ion Xpress™ barcode adapters (Thermo Fisher Scientific, Inc.). Each library was purified using AMPure XP beads (Beckman Coulter, Inc.) and quantified using a Life Technologies™ Qubit^®^ 3.0 fluorometer (Thermo Fisher Scientific, Inc.). The size distributions of the libraries were verified using a High Sensitivity DNA kit with a 2100 Bioanalyzer (both Agilent Technologies, Inc.).

Libraries were constructed from cffDNA extracted from the plasma of pregnant women using the Life Technologies™ Ion Plus Fragments Library kit (Thermo Fisher Scientific, Inc.) with the SureSelect Target Enrichment kit PTN Hyb Module Box2 and SureSelect TE Reagent kit (both Agilent Technologies, Inc.). First, 30 µl cffDNA, 9.5 µl 5X End Repair buffer, 0.5 µl End Repair enzyme and 10 µl nuclease-free water were mixed per reaction for end repair of the cffDNA. Subsequently, the library was ligated to a unique barcode and universal adapter using Life Technologies™ Ion Xpress™ barcode adapters (Thermo Fisher Scientific, Inc.). Each library was concentrated to 3.4 µl, and then 13 µl Hybridization Buffer mix, 5.6 µl SureSelect Block mix and 2 µl SureSelect Library were added, followed by incubation for 16 or 24 h at 65°C to capture the target regions. Each positive library was enriched using Life Technologies™ Dynabeads MyOne Streptavidin T1 (Thermo Fisher Scientific, Inc.). The purified libraries were quantified using a Qubit^®^ 3.0 fluorometer. The size distributions of the libraries were verified using a High Sensitivity DNA kit with a 2100 Bioanalyzer (Agilent Technologies, Inc.).

### Template preparation and enrichment and NGS

Each library was diluted to 100 pM based on its concentration quantified with the Qubit^®^ 3.0 fluorometer. Subsequently, ten libraries (for blood samples) or four libraries (for plasma) were mixed equally and diluted to 100 pM, respectively. The diluted sample was amplified through emulsion PCR on Ion Proton™ HiQ™ ion sphere particles (ISPs) using a Life Technologies™ Ion OneTouch™ 2 Instrument according to the manufacturer\'s instructions. Template-positive ISPs were enriched using a Life Technologies™ Ion OneTouch™ ES Instrument, according to the manufacturer\'s instructions.

The enriched templates were loaded onto a Life Technologies™ Ion PI™ chip kit V2 and sequenced on the Life Technologies™ Ion Torrent Proton semiconductor sequencing platform. All instruments and reagents were from Thermo Fisher Scientific, Inc.

### Haplotype

Sequences with a high quality of Q≥20 were mapped to the human reference sequence hgl9 (Genome Reference Consortium, GRCh37) (sanger.ac.uk/science/data/genome-reference-consortium). The generated BAM files were then subjected to the quality control process using the analysis system of Proton semiconductor sequencing platform. The significance index, which must be met for continued analysis, is achieved when the fraction of the target region with coverage in excess of 30X \>85% ([@b27-mmr-22-02-1547]). Variants associated to Ion AmpliSeq Thalassemia panel were screened using the Genome Analysis Toolkit (GATK; version 3.4) ([broadinstitute.org/gatk/](broadinstitute.org/gatk/)) ([@b28-mmr-22-02-1547]). Variants were annotated using the bioinformatics software tool Annovar (docopenbio.readthedocs.io/projects/annovar/en/latest/) as well as in-house *ad hoc* bioinformatics tools ([@b28-mmr-22-02-1547]). The detected variants were subjected to a rigorous manual curation process that included querying variant databases \[e.g., dbSNP ([ncbi.nlm.nih.gov/SNP/](ncbi.nlm.nih.gov/SNP/)), Exome Aggregation Consortium ([exac.broadinstitute.org](exac.broadinstitute.org)), 1,000 Genomes (gloshospitals.nhs.uk/about-us/research-our-hospitals/100000-genomes-project/) and Clinvar databases ([ncbi.nlm.nih.gov/clinvar/](ncbi.nlm.nih.gov/clinvar/))\] and a literature review. Common variation loci were screened in samples from the parents and their first child, according to the exclusion criterion MAF \>0.1%. Subsequently, genotype information was used to determine the parental haplotype and its linkage to the pathogenic allele, following the rules of Mendelian inheritance.

### RHDO sequential probability ratio test (SPRT)

High quality plasma sequence data were mapped to the human reference sequence hgl9 (Genome Reference Consortium GRCh37), and variants were called using GATK (version 3.4) ([@b29-mmr-22-02-1547]) with parameters optimized for thalassemia. First, gDNA samples from the mother, father and proband ('trio') were subjected to analysis of the target region. For paternal inheritance, SNPs that were homozygous in the mother and heterozygous in the father were used. Paternal haplotypes that were inherited by the proband or absent in the proband were thus identified. For maternal inheritance, SNPs that were heterozygous in the mother and homozygous in the father were used. Maternal haplotypes (linked or not linked to the proband\'s mutation) were determined. Secondly, the target region of the pregnant mother was determined from the plasma cffDNA. Detection of paternal specific alleles in the maternal plasma revealed the inheritance of the paternal haplotype, which could be either linked or not linked to the proband\'s mutation, from the father. Maternal inheritance was determined through RHDO analysis as previously described ([@b24-mmr-22-02-1547]). Using the fractional fetal DNA concentration, SPRT classification was used to determine the statistical significance of the allelic imbalance within a haplotype block for RHDO analysis. Cumulative sequencing counts of SNP alleles from plasma cffDNA were inputted to the SPRT in order of chromosomal position ([@b30-mmr-22-02-1547]), until a classification was possible. The SPRT curve was calculated according to the following formula:

Upper boundary

=

(

ln

1200

)

/

N

−

ln

d

ln

g

Lower boundary

=

(

ln

1

/

1200

)

/

N

−

ln

d

ln

g

,

![](MMR-22-02-1547-g00.jpg)

![](MMR-22-02-1547-g01.jpg)

Where

d

=

1

−

q

1

1

−

q

0

![](MMR-22-02-1547-g02.jpg)

and

g

=

q

1

(

1

−

q

0

)

q

0

(

1

−

q

1

)

![](MMR-22-02-1547-g03.jpg)

'Upper boundary' and 'lower boundary' refer to the upper and lower bounds, respectively ([@b3-mmr-22-02-1547]). N is the number of samples for all sites used for classification. q0 represents fetal inheritance of maternal haplotype 2, based on statistics from the haplotype 1 ratio. q1 is the case of fetal inheritance of maternal haplotype 1, from statistics of the haplotype 1 ratio. Haplotype 1 was defined as the upper bound in this assay, and haplotype 2 as the lower bound. Using the SPRT algorithm, the filtered points were used to calculate the cumulative depth and cumulative frequency of variations.

### Analysis of amniotic fluid

All amniotic fluid samples were specifically amplified as aforementioned using the α-thalassemia genetic diagnostic kit by gap-PCR and the thalassemia RDB genotyping assay kit (both DaAN Gene Co., Ltd.), according to the manufacturer\'s instructions. Subsequently, the target products of gap-PCR were detected by agarose gel electrophoresis.

Results
=======

### Hematological parameters and genotypes of eight recruited families with thalassemia

Thalassemia screening generally includes the detection of mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), HBA (α2β2) and HBA2 (α2δ2). The MCV reference value usually falls within the range 80--100 fl while the MCH reference value is in the 27--34 pg range. In addition, the HBA reference value is within 96.5--97.5%, and the HBA2 reference value 2.5--3.5%.

The results for hypochromic anemia in all families are presented in [Table I](#tI-mmr-22-02-1547){ref-type="table"}. The MCV and MCH values of all the subjects were found to be lower than normal values. The HBA2 values of four individuals were lower than normal values. The HBA2 values of another two individuals were normal and the HBA2 values of ten individuals were higher than normal values.

The results for microcytic anemia in all families are shown in [Table I](#tI-mmr-22-02-1547){ref-type="table"}. Moreover, in total, three families exhibited α-thalassemia, four families had β-thalassemia and one family had both α- and β-thalassemia ([Figs. S1](#SD1-mmr-22-02-1547){ref-type="supplementary-material"}--[S3](#SD1-mmr-22-02-1547){ref-type="supplementary-material"}).

### Sequencing statistics

For blood DNA samples, the average number of total raw bases was 728,011,603 (range, 431,538,785-1,100,881,706). The average read length was 137 bp. The mean percentage of sequencing reads mapped to the reference hg19 genome was 98%. After the filtering of low-quality reads, polyclonal reads and primer dimer reads, the number of sequenced bases with Q≥20 ranged between 345,306,892-921,298,977 ([Fig. 1A and B](#f1-mmr-22-02-1547){ref-type="fig"}). After mapping to the hg19 genome and the removal of Q\<20 reads, polyclonal reads and primer dimer reads, the remaining sequences were mapped to the target regions, containing 195 SNPs for α-thalassemia and 275 SNPs for β-thalassemia (data not shown). Furthermore, an average depth of coverage of 118X (range, 70-178X) was obtained for all 470 SNPs across the 24 blood samples (data not shown).

For plasma DNA samples, the average number of total raw bases was 2,986,588,135 (range, 2,509,364,780-3,482,168,649). The average read length was 151 bp. The mean percentage of sequencing reads mapped to the reference hg19 genome was 98%. After filtering of low-quality reads, polyclonal reads and primer dimer reads, the number of sequenced bases with Q-values ≥20 ranged between 2,157,982,851-2,975,281,429 ([Fig. 1C and D](#f1-mmr-22-02-1547){ref-type="fig"}). Finally, an average depth of coverage of 836X (range, 702--975X) was obtained for all 470 SNPs across the eight plasma samples.

### Haplotypes

The fractional fetal DNA concentration in the maternal plasma, f, can be calculated from sequencing data as f=2p/(p + q), where p is the number of sequenced reads of the fetal specific allele and q is the read count of the other allele, which is shared by the maternal and fetal genomes ([@b31-mmr-22-02-1547]). The average percentage of fetal DNA in maternal plasma was found to be 17.3% (range, 15--19%) (data not shown). For the father, mother and child, the chromosome 11 and 16 haplotypes were sorted into 16 and 87 different SNP categories, respectively (data not shown). An example of chromosome 11 and 16 haplotypes for a family is illustrated in [Fig. 2](#f2-mmr-22-02-1547){ref-type="fig"}. The genotype information of the parents was used to determine the parental haplotype and its linkage to the pathogenic allele according to Mendelian inheritance laws ([@b32-mmr-22-02-1547]). Detailed information regarding the haplotypes associated with the pathogenic allele is provided in [Table II](#tII-mmr-22-02-1547){ref-type="table"}.

### Genetic analysis of paternal and maternal genotypes

The genetic results for the father were based on an analysis of SNPs that were heterozygous in the plasma, while being homozygous in the mother and heterozygous in the father, or homozygous in both, but with different genotypes. Overall, the eight fetuses inherited haplotype I of their father ([Table III](#tIII-mmr-22-02-1547){ref-type="table"}). For maternal inheritance, SNPs were analyzed where the mother was heterozygous and the father was homozygous, allowing the detection of slight allelic imbalances in the maternal plasma using RHDO and SPRT.

In total, eight fetuses inherited haplotype I from their mother. The results of RHDO SPRT for family 1 are illustrated in [Fig. 3](#f3-mmr-22-02-1547){ref-type="fig"} and [Tables IV](#tIV-mmr-22-02-1547){ref-type="table"} and [V](#tV-mmr-22-02-1547){ref-type="table"}. A summary of the results for all eight fetal genotypes is shown in [Table VI](#tVI-mmr-22-02-1547){ref-type="table"}. It was found that three fetuses (from family 1, family 3 and family 5) had no inheritance of their parents\' pathogenic sites; three fetuses (from family 4, family 7 and family 8) only inherited the pathogenic site of one parent; and one fetus (family 2) inherited the pathogenic sites of both parents.

### Accuracy of fetus haplotype determination

To further verify the accuracy of fetal haplotype inference for NIPT, the results obtained from maternal plasma DNA sequencing were validated using gap-PCR and RDB of fetal gDNA collected from amniotic fluid cells. The non-invasive results were 100% consistent with the gap-PCR and RDB results from amniotic fluid for these eight samples ([Figs. 1](#f1-mmr-22-02-1547){ref-type="fig"} and [2](#f2-mmr-22-02-1547){ref-type="fig"}).

Discussion
==========

The discovery of cffDNA in maternal plasma has allowed for the possibility of non-invasive prenatal diagnosis of genetic disorders. Applications of cffDNA include screening for aneuploidies, prenatal diagnosis of mutation based monogenic diseases, and fetal Rhesus D status determination ([@b33-mmr-22-02-1547]). These techniques are based on qualitative and quantitative comparisons of cffDNA with the background of maternal cffDNA in maternal plasma ([@b10-mmr-22-02-1547]). Non-invasive prenatal screening for aneuploidies based on NGS was rapidly incorporated into routine clinical practice ([@b30-mmr-22-02-1547]). Accordingly, guidelines for clinical application and committee guidance regarding NIPT have been issued by numerous medical societies, including the Society of Obstetricians and Gynaecologists of Canada ([@b34-mmr-22-02-1547]), the Italian College of Fetal Maternal Medicine ([@b35-mmr-22-02-1547]), the American College of Medical Genetics and Genomics ([@b36-mmr-22-02-1547]), the National Society of Genetic Counselors and the International Society for Prenatal Diagnosis ([@b37-mmr-22-02-1547]). Furthermore, genome-wide micro deletion or micro duplication syndromes have been screened for in an expanded NIPT protocol.

Maternal plasma cffDNA includes cffDNA and maternal cffDNA, and half of fetal alleles are inherited paternally. Xiong *et al* ([@b38-mmr-22-02-1547]) reported one case of this type of non-invasive prenatal diagnosis using PCR and NGS for the detection of a paternal pathogenic mutation. Yan *et al* ([@b39-mmr-22-02-1547]) and Ho *et al* ([@b40-mmr-22-02-1547]) reported exclusion of fetal homozygous α-thalassemia based on the presence of the father\'s SNP within the break point sequence. However, these methods can only be used to exclude fetal risk and do not provide the exact genotype of the fetus. Quantification of specific alleles can provide accurate fetal genotype results. In this manner, several monogenic diseases have been successfully detected non-invasively using cffDNA and PCR based methods ([@b41-mmr-22-02-1547],[@b42-mmr-22-02-1547]). NGS-based approaches have also been applied to non-invasive prenatal diagnosis of β-thalassemia through deduction of the fetal inheritance of maternally transmitted mutations via the quantification of the relative levels of haplotypes with SNP alleles in and around the targeted gene. Recently, Yang *et al* ([@b43-mmr-22-02-1547]) reported a robust and versatile NGS-based cffDNA allelic molecule counting system termed the cffDNA barcode enabled single molecule test, which was developed for the non-invasive prenatal diagnosis of β-thalassemia. However, these methods mainly aim to identify SNV-associated thalassemia and have not been applied to CNV-associated thalassemia ([@b44-mmr-22-02-1547]).

The present study aimed to develop a system for non-invasive prenatal detection of paternal and maternal mutations associated with α- and β-thalassemia. It was demonstrated that multiplex PCR or target capture combined with NGS of highly heterozygous SNPs within the 10 kb flanking region of the gene of interest effectively reduced the target region size for detection of paternal and maternal mutations. Furthermore, this technique may be used to detect both α- and β-thalassemia, as well as SNPs and large deletion mutations. gDNA of the parents and their children were amplified via multiplex PCR using a thalassemia panel, and cffDNA was captured with a set of thalassemia probes. The products were sequenced using NGS. Subsequently, the parental haplotype was determined using a trio-based strategy. The genetic results for the father were based on analysis of SNPs that were heterozygous in the plasma and were also either homozygous in the mother and heterozygous in the father, or homozygous in both, but of different genotypes. For maternal inheritance, SNPs were analyzed where the mother was heterozygous and the father was homozygous, and whether a slight allelic imbalance was present in maternal plasma was investigated using RHDO SPRT. In total, three cases of α-thalassemia, four of β-thalassemia and one case of combined α- and β-thalassemia were successfully diagnosed using this non-invasive prenatal diagnosis method, and the results exhibited high consistency with the traditional invasive method. Fetal genotypes were successfully deduced non-invasively for eight families. The non-invasively determined haplotypes of the eight fetuses were identical with those obtained through invasive prenatal diagnosis procedures, with an accuracy rate of 100% in the target region.

In the present study, the average percentage of fetal DNA was 17.3%. As accuracy is affected by the fetal fraction, in follow-up studies, additional cases should be tested, especially using samples collected in early gestation, in order to thoroughly evaluate the method prior to clinical application. This study, however, has provided an example of non-invasive prenatal diagnosis of single gene diseases that can be exploited for other single gene diseases, such as congenital adrenal hyperplasia, Ellis van Creveld syndrome, hemophilia and Hunter\'s syndrome. Overall, multiplex PCR and target capture combined with NGS of highly heterozygous SNPs flanking the gene of interest is an effective method to reduce sequencing costs.

In conclusion, the routine prenatal diagnosis method for thalassemia currently used clinically is gap-PCR and RDB of fetal DNA, which can be acquired from ultrasound mediated abdominal biopsy, amniocentesis or cordocentesis. However, these invasive procedures may increase the risk of miscarriage and cause anxiety for pregnant women. The present study demonstrated the feasibility of non-invasive prenatal diagnosis of thalassemia using cffDNA from the plasma of pregnant women through target capture and NGS combined with RHDO analysis. Furthermore, this method can be used to detect deletion and mutation-based thalassemia at a relatively lower cost, as well as to investigate other diseases caused by CNVs and SNVs.
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###### 

Results of hypochromic anemia analysis for all families.

  Family number   Family member   MCV, fl   MCH, pg   HBA, %   HBA2, %   Type
  --------------- --------------- --------- --------- -------- --------- -------------------------------------
  1               Mother          62.2      19.7      97.9     2.5       α^QS^α/αα
                  Father          69.4      20.2      97.8     2.2       \--^SEA^/αα
  2               Mother          64.6      19.6      97.7     2.3       \--^SEA^/αα
                  Father          63.4      18.9      95.9     2.2       -α^3.7^/αα
  3               Mother          72.5      22.4      94.2     5.2       β^N^/β^+^ (−28A\>G)
                  Father          76.9      23.9      92.0     5.7       β^N^/β° (IVS-2-654)
  4               Mother          58.5      20.2      93.6     6.0       β^N^/β° (CD41-42_CTTT)
                  Father          63.7      22.2      95.5     4.5       β^N^/β^+^ (−28A\>G)
  5               Mother          79.9      25.4      97.1     2.9       α^CS^α/αα
                  Father          63.2      19.9      97.9     2.1       \--^SEA^/αα
  6               Mother          65.0      21.0      93.2     6.5       \--^SEA^/αα& β^N^/β° (CD41-42_CTTT)
                  Father          61.8      19.7      92.5     5.9       β^N^/β° (CD41-42_CTTT)
  7               Mother          66.8      21.1      93.2     6.0       β^N^/β^0N^(CD71-72+A)
                  Father          72.4      22.2      95.1     4.9       β^N^/β^+^ (−28A\>G)
  8               Mother          60.4      18.5      94.0     6.0       β^N^/β° (CD41-42_CTTT)
                  Father          59.9      19.1      92.1     5.9       β^N^/β° (CD17A\>T)

MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; HBA, adult hemoglobin α2β2; HBA2, adult hemoglobin, α2δ2.

###### 

Haplotypes associated with the pathogenic allele.

  Family number   Maternal haplotype    Paternal haplotype
  --------------- --------------------- --------------------
  1               Hap II                Hap II
  2               Hap I                 Hap I
  3               Hap II                Hap II
  4               Hap II                Hap I
  5               Hap II                Hap II
  6               α: Hap I; β: Hap II   Hap II
  7               Hap I                 Hap II
  8               Hap II                Hap I

Hap, haplotype.

###### 

Parental genetic source results for family 1.

  Chr     Position   Hap I of father   Hap II of father   Hap I of mother   Hap II of mother   Fetal   Inherited
  ------- ---------- ----------------- ------------------ ----------------- ------------------ ------- -----------
  Chr11   4178706    T                 C                  C                 C                  C:T     Hap I
  Chr11   4186666    T                 C                  C                 C                  C:T     Hap I
  Chr11   4415266    C                 A                  A                 A                  A:C     Hap I
  Chr11   4415319    A                 G                  G                 G                  G:A     Hap I
  Chr11   5452526    G                 A                  A                 A                  A:G     Hap I
  Chr11   5546041    C                 G                  G                 G                  G:C     Hap I
  Chr11   5550754    C                 G                  G                 G                  G:C     Hap I
  Chr11   5554559    C                 G                  G                 G                  G:C     Hap I
  Chr11   5573193    T                 A                  A                 A                  A:T     Hap I
  Chr16   142200     A                 G                  G                 G                  G:A     Hap I
  Chr16   218532     C                 SEA                T                 T                  T:C     Hap I
  Chr16   219497     G                 SEA                G                 G                  G:A     Hap I
  Chr16   248418     C                 T                  T                 T                  T:C     Hap I
  Chr16   306062     G                 C                  C                 C                  C:G     Hap I
  Chr16   326525     C                 A                  A                 A                  A:C     Hap I
  Chr16   754288     T                 C                  C                 C                  C:T     Hap I
  Chr16   893160     A                 G                  G                 G                  G:A     Hap I

Chr, chromosome; hap, haplotype; SEA, Southeast Asian deletion.

###### 

SPRT classification process for relative haplotype dosage analysis of type α single nucleotide polymorphisms near the p-ter of chromosome 16 in family 1.

  Position   Hap I count   Hap II count   Hap I cum.   Hap II cum.   Total reads   Hap I fraction   Upper boundary   Lower boundary   SPRT
  ---------- ------------- -------------- ------------ ------------- ------------- ---------------- ---------------- ---------------- --------------
  234632     23            25             23           25            48            0.4792           0.8506           0.0569           Unclassified
  256278     84            108            107          133           240           0.4458           0.5331           0.3744           Unclassified
  281299     97            95             204          228           432           0.4722           0.4978           0.4096           Unclassified
  281885     85            109            289          337           626           0.4617           0.4842           0.4233           Unclassified
  306243     56            68             345          405           750           0.4600           0.4791           0.4283           Unclassified
  311853     84            110            429          515           944           0.4544           0.4739           0.4336           Unclassified
  312253     89            104            518          619           1,137         0.4556           0.4705           0.4370           Unclassified
  312635     94            95             612          714           1,326         0.4615           0.4681           0.4394           Unclassified
  315557     92            101            704          815           1,519         0.4635           0.4663           0.4412           Unclassified
  317393     89            90             793          905           1,698         0.4670           0.4650           0.4425           Hap I
  319761     97            96             890          1,001         1,891         0.4707           0.4638           0.4437           Hap I
  336660     98            95             988          1,096         2,084         0.4741           0.4629           0.4446           Hap I
  377617     81            89             1,069        1,185         2,254         0.4743           0.4622           0.4453           Hap I
  390780     96            97             1,165        1,282         2,447         0.4761           0.4615           0.4460           Hap I
  423420     89            87             1,254        1,369         2,623         0.4781           0.4610           0.4465           Hap I
  427516     72            74             1,326        1,443         2,769         0.4789           0.4606           0.4469           Hap I
  641445     84            105            1,410        1,548         2,958         0.4767           0.4602           0.4473           Hap I
  651517     98            96             1,508        1,644         3,152         0.4784           0.4598           0.4477           Hap I
  674029     87            97             1,595        1,741         3,336         0.4781           0.4594           0.4480           Hap I
  678843     88            90             1,683        1,831         3,514         0.4789           0.4592           0.4483           Hap I
  878161     88            106            1,771        1,937         3,708         0.4776           0.4589           0.4486           Hap I
  880431     85            109            1,856        2,046         3,902         0.4757           0.4586           0.4489           Hap I
  928867     87            94             1,943        2,140         4,083         0.4759           0.4584           0.4491           Hap I
  940706     85            102            2,028        2,242         4,270         0.4749           0.4582           0.4493           Hap I

SPRT, sequential probability ratio test; hap, haplotype.

###### 

SPRT classification process for relative haplotype dosage analysis of type β single nucleotide polymorphisms near the p-ter of chromosome 16 in family 1.

  Position   Hap I count   Hap II count   Hap I cum.   Hap II cum.   Total reads   Hap I fraction   Upper boundary   Lower boundary   SPRT
  ---------- ------------- -------------- ------------ ------------- ------------- ---------------- ---------------- ---------------- --------------
  151136     129           102            129          102           231           0.5584           0.6287           0.4638           Unclassified
  192314     136           92             265          194           459           0.5773           0.5878           0.5048           Unclassified
  225159     113           99             378          293           671           0.5633           0.5746           0.5179           Unclassified
  231541     33            24             411          317           728           0.5646           0.5724           0.5201           Unclassified
  235660     126           93             537          410           947           0.5671           0.5664           0.5262           Hap I
  241210     125           102            662          512           1,174         0.5639           0.5625           0.5300           Hap I
  258741     134           92             796          604           1,400         0.5686           0.5599           0.5327           Hap I
  326826     112           112            908          716           1,624         0.5591           0.5580           0.5345           Hap I
  534954     138           92             1,046        808           1,854         0.5642           0.5565           0.5360           Hap I
  902172     66            45             1,112        853           1,965         0.5659           0.5560           0.5366           Hap I
  903426     122           83             1,234        936           2,170         0.5687           0.5550           0.5375           Hap I
  905559     106           78             1,340        1,014         2,354         0.5692           0.5544           0.5382           Hap I
  922134     128           99             1,468        1,113         2,581         0.5688           0.5536           0.5389           Hap I
  935560     133           96             1,601        1,209         2,810         0.5698           0.5530           0.5395           Hap I
  937413     129           89             1,730        1,298         3,028         0.5713           0.5526           0.5400           Hap I
  945728     110           112            1,840        1,410         3,250         0.5662           0.5521           0.5404           Hap I
  947817     131           100            1,971        1,510         3,481         0.5662           0.5517           0.5408           Hap I

SPRT, sequential probability ratio test; hap, haplotype; Cum, cumulative count for alleles on Hap I/Hap II.

###### 

Results for the eight fetal genotypes.

  Fetus number   Haplotype inherited from father   Haplotype inherited from mother   Type
  -------------- --------------------------------- --------------------------------- ---------------------------
  1              Hap I                             Hap I                             αα/αα
  2              Hap I                             Hap I                             \--^SEA^/-α^3.7^
  3              Hap I                             Hap I                             β^N^/β^N^
  4              Hap I                             Hap I                             β^+^\[-28(A\>G)\]/β^N^
  5              Hap I                             Hap I                             αα/αα
  6              Hap I                             Hap I                             \--SEA/αα, β^N^/β^N^
  7              Hap I                             Hap I                             β°\[CD71-72(+A)\]/β^N^
  8              Hap I                             Hap I                             β°\[CD17(AAG\>TAG)\]/β^N^

Hap, haplotype; SEA, Southeast Asian deletion.

[^1]: Contributed equally
